Acquisition - October 10, 2025
Novo Nordisk to acquire Akero Therapeutics
Novo Nordisk has entered into a definitive agreement to acquire Akero Therapeutics, a publicly held clinical-stage company developing innovative treatments for patients with serious metabolic diseases marked by a high unmet medical need.
Clinical Trials - October 8, 2025
PharmNovo secures CTA approval in Spain
The company's clinical trial application (CTA) for a Phase IIa proof of concept (PoC) study investigating the safety and efficacy of lead candidate PN6047 in patients with neuropathic pain has been approved in Spain.
Pharma Business - October 8, 2025
Xspray Pharma’s FDA approval delayed
FDA has issued a Complete Response Letter regarding Xspray’s New Drug Application for Dasynoc, referring to GMP observations at a contract manufacturer.
Business article - October 6, 2025
Novo Nordisk ends collaboration with Heartseed
As part of Novo Nordisk's restructuring, the company has chosen to discontinue its cell therapy collaboration with Heartseed.
Financing - September 30, 2025
Orexo US awarded USD 8 million by BARDA
The company's wholly owned US subsidiary, Orexo US has been awarded funding by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response in the US Department of Health and Human Services.
Global report - September 29, 2025
AstraZeneca switch to direct US listing, keeps UK listing
AstraZeneca plans to harmonize its share listing structure to deliver "a global listing for global investors in a global company".
